Previous close | 28.40 |
Open | 29.27 |
Bid | 28.13 x 50000 |
Ask | 28.97 x 50000 |
Day's range | 29.27 - 29.27 |
52-week range | 22.35 - 34.48 |
Volume | |
Avg. volume | 170 |
Market cap | 56.418B |
Beta (5Y monthly) | 0.29 |
PE ratio (TTM) | 49.61 |
EPS (TTM) | 0.59 |
Earnings date | N/A |
Forward dividend & yield | 0.37 (1.29%) |
Ex-dividend date | 28 Mar 2024 |
1y target est | N/A |
AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.
Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.
Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.